Gilead resubmits new HIV drug Lenacapavir marketing application
- Why are vegetarians more likely to suffer from depression than meat eaters?
- Small wireless device implanted between skin and skull helps kill cancer cells
- Will the mRNA vaccine that can cure cancer come out near soon?
- Allogeneic T-cell therapy set for landmark first approval
- Boston University denies that the new COVID strain they made has 80% fatality rate
- A new generation of virus-free CAR-T cell therapy
Gilead resubmits new HIV drug Lenacapavir marketing application
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Where do the bacteria in the human gut come from?
Gilead resubmits new HIV drug Lenacapavir marketing application, requiring only two doses per year
On June 27 , Gilead announced that it had resubmitted to the U.S. Food and Drug Administration (FDA) its development of a long-acting HIV-1 capsid inhibitor, Lenacapavir, for the treatment of severe multidrug-resistant (MDR) HIV-1 infection. (HTE) New Drug Application (NDA) for HIV-1 infection in patients .
If eventually approved, Lenacapavir would be the first and only HIV-1 regimen to be administered twice a year.
This time, Gilead resubmitted the NDA for Lenacapavir .
In February 2022 , the FDA issued a Complete Response Letter ( CRL ) questioning the Chemical Manufacturing and Control ( CMC ) issue of the borosilicate glass vial’s compatibility with Lenacapavir injectable solution .
The NDA resubmission contains comprehensive CMC data to support the compatibility of Lenacapavir with alternative vial types made of aluminosilicate glass.
In addition, the NDA is supported by extensive preclinical and early clinical study data and data from the Phase 2/3 CAPELLA study evaluating the antiviral activity of Lenacapavir administered subcutaneously every six months in combination with other antiretroviral drugs For persons with severe treatment experience with multidrug-resistant HIV-1 infection.
Once the NDA is accepted by the FDA , a new Prescription Drug User Fee Act (PDUFA) date will be set.
“Due to resistance to multiple antiretroviral therapies, some people living with HIV have very limited treatment options,” said Jared Baeten , MD, vice president of HIV clinical development at Gilead Sciences . “We are committed to addressing unmet needs and Recognize the urgency of filling critical treatment gaps for patients with multidrug-resistant HIV whose virus is no longer responsive to current treatments.”
Gilead resubmits new HIV drug Lenacapavir marketing application
(source:internet, reference only)
Disclaimer of medicaltrend.org